Assembly Bio CEO John McHutchison to retire Dec 31; Jason Okazaki to succeed as CEO Jan 1, 2023

ASSEMBLY BIOSCIENCES, INC.

John G. McHutchison to retire as CEO effective Dec 31, 2022; remains board member and chair of Science & Technology Committee.
Jason A. Okazaki, current President and COO, appointed President and CEO and board member effective Jan 1, 2023.
Okazaki joined Assembly Bio in 2020; previously SVP Legal at Gilead; promoted to COO in 2021 and President in 2022.
Dr. McHutchison led expansion beyond core HBV inhibitors to HDV entry inhibitor, interferon-α receptor agonist, and herpes programs.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

John G. McHutchison

Chief Executive Officer

ASMB · ASSEMBLY BIOSCIENCES, INC.

Effective: 2022-12-31
Successor: Jason A. Okazaki
Filed: October 5, 2022, 7:59 PM ET

John G. McHutchison, A.O., M.D. will retire from his role as Chief Executive Officer of the Company, effective December 31, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

John G. McHutchison changed role as Chief Executive Officer at ASSEMBLY BIOSCIENCES, INC..

Action: retire
Role: Chief Executive Officer

Exact text from the filing

John G. McHutchison, A.O., M.D. will retire from his role as Chief Executive Officer of the Company, effective December 31, 2022.

View on SEC.gov

ASSEMBLY BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-22-019311

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.